Kimmtrak
Kimmtrak was approved in 2022 for advanced uveal melanoma, a form of eye cancer, as well as cases where the cancer isn’t able to be surgically removed. The first drug of its kind, it’s taken intravenously and is supposed to work by allowing immune cells to better target certain “cold” tumor cells that would otherwise go undetected.
While this class of drugs may have a bright future ahead, they won’t come cheap. A year’s supply of Kimmtrack will cost $975,520, according to GoodRx, making it the second most expensive new drug of 2022 so far.
